Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study

Trial Profile

Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Chiauranib (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Chipscreen Biosciences
  • Most Recent Events

    • 21 Nov 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.
    • 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
    • 29 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top